- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06544876
Balance Control and Recovery in Diabetes Peripheral Neuropathy (DPN)
In this study the effects of diabetic peripheral neuropathy will be assessed on balance control, balance recovery, and muscle electrical activity in adults over 50 years.
Aim 1: Determine muscle activity and balance control during a sit-to-stand in adults age above 50 with and without diabetic peripheral neuropathy.
Aim 2: Assess local balance recovery and latency responses to lateral surface perturbation during quiet standing.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Diabetic peripheral neuropathy (DPN) is a common condition affecting patients with diabetes. The prevalence of DPN increases with age and the duration of having diabetes. Approximately 30% of patients with diabetes have peripheral neuropathy globally, and 4.5 million Americans have DPN.
DPN typically affects more distal peripheral nerve branches, resulting in sensory loss. DPN causes axonal damage and leads to a loss of muscle strength. These degenerative effects significantly contribute to fall risks and feelings of instability.
Falls most commonly occur during transitional tasks such as the sit-to-stand (STS) and stand-to-sit (StandTS). The overall objective of this study to assess the effects of DPN on balance control and muscle activity during transitional tasks (STS and StandTS) and during lateral perturbation while standing.
Study procedures:
- Measures of body weight, height, and limb diameter and measuring including leg length, knee width, elbow width, wrist width, and hand thickness.
- Measures of sensation of the big toe and heel area for both legs.
- Surface sensors will be placed on the leg muscles using non-allergic double adhesive tape.
- Participants will sit down and stand up on a chair with adjustable height.
- Then, participants will be asked to stand on a treadmill holding a ruler. The treadmill will slightly move left and right, and the muscle activity and balance control will be evaluated.
- Finally, muscle strength of the legs' muscles will be collected.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78712
- Recruiting
- The University of Texas at Austin
-
Contact:
- Mohsen Alighanbari, M.Sc.
- Phone Number: 512-471-9228
- Email: m.alighanbari@utexas.edu
-
Contact:
- Lisa Griffin, Ph.D.
- Phone Number: 5124712786
- Email: l.griffin@austin.utexas.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Type II diabetes with peripheral neuropathy
Exclusion Criteria:
- Foot ulcer
- Partial amputation
- Have experience of Stroke
- Painful neuropathy
- Inability to stand or walk independently
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: healthy younger adult
|
test for balance during movement from sitting to standing
test for balance during movement from standing to sitting
test for balance recovery following perturbation
measure of peripheral nerve diameter
|
|
Active Comparator: Healthy older adult
|
test for balance during movement from sitting to standing
test for balance during movement from standing to sitting
test for balance recovery following perturbation
measure of peripheral nerve diameter
|
|
Experimental: older adult with diabetic peripheral neuropathy
|
test for balance during movement from sitting to standing
test for balance during movement from standing to sitting
test for balance recovery following perturbation
measure of peripheral nerve diameter
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Center of pressure using force plate
Time Frame: First session (immediately after intervention)
|
Center-of-pressure sway will be assessed between groups.
As participants sit down or stand up from a chair on the force plates, the ground reaction force will be collected.
Then, using a mathematical approach, an ellipse will be fitted to the data to calculate the sway area.
A higher sway area indicates an impairment during balance control.
|
First session (immediately after intervention)
|
|
Center of mass using Vicon cameras.
Time Frame: First session (immediately after intervention)
|
Center-of-mass sway volume will be assessed as the participant will walk in front of a high-speed camera, which will be recorded using the retroreflective markers.
Then, a mathematical approach will be used to fit an ellipsoid to the data samples for each group.
Higher sway volume means impairment in balance.
|
First session (immediately after intervention)
|
|
Joint moment using Nexus software
Time Frame: First session (immediately after intervention)
|
Joint moments will be assessed between groups using Vicon and force plates.
This variable will be obtained using Nexus software, which combines both the inputs from Vicon and force plates.
|
First session (immediately after intervention)
|
|
Local dynamic stability using Motek and Vicon system
Time Frame: First session (immediately after intervention)
|
Local dynamic stability will be assessed using the Motek treadmill and Vicon cameras.
The Motek treadmill will provide the left and right perturbation, and the Vicon system will collect the kinematic data.
Then, the MATLAB code will calculate local dynamic stability to identify impairment in balance recovery.
|
First session (immediately after intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Muscle amplitude using root mean square
Time Frame: First session (immediately after intervention)
|
Muscle amplitude will be collected using Delsys Tringo wireless surface electromyography (EMG).
The EMG electrodes will be attached with double adhesive tape.
Then, EMG amplitudes will be assessed using the root mean square technique in MATLAB software.
Higher amplitude represents higher muscle activity.
|
First session (immediately after intervention)
|
|
Muscle onset time using electromyography
Time Frame: First session (immediately after intervention)
|
The muscle onset time will be assessed using MATLAB code.
An abrupt change in the EMG trace is defined as a muscle onset time.
Any change in EMG onset time represents impairment in neuromuscular junctions or muscle and nerve electrical conduction.
|
First session (immediately after intervention)
|
|
Muscle co-activation index using EMG
Time Frame: First session (immediately after intervention)
|
The coactivation index will be assessed between two muscles in the same participant using MATLAB syntax.
An increase in muscle coactivation represents an increase in active joint stiffness.
This increase in active joint stiffness reduces the resultant joint moment, leading to impaired smoothness of movement and reducing the ability to perform daily activities.
|
First session (immediately after intervention)
|
|
Muscle energy frequency using EMG data
Time Frame: First session (immediately after intervention)
|
Wavelet transform can identify the contribution of different muscle fibers (large or small, fast or slow twitch fibers) in the same task.
Assessment of this method indicates what fiber type is affected by DPN.
|
First session (immediately after intervention)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00001512
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.